Philadelphia, Pennsylvania
Phase 1 colorectal cancer trials in Philadelphia, PA
27 Phase 1 colorectal cancer studies are recruiting participants at sites in Philadelphia as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Philadelphia at a glance
- 27 studies are recruiting at a site in Philadelphia.
- By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (11).
- By sponsor: industry (21), university, hospital or other (6).
- Most recent update to one of these records: November 12, 2026.
Studies recruiting in Philadelphia
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- Sidney Kimmel Cancer Center
- Registry record
- NCT07458347 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Univ of Pennsylvania, Abramson Cancer Center
- Registry record
- NCT07020221 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- Fox Chase Cancer Center · University of Pennsylvania
- Registry record
- NCT07213791 · updated
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Sydney Kimmel Cancer Center
- Registry record
- NCT06720987 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT07542704 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- University of Pennsylvania
- Registry record
- NCT03526835 · updated
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Fox Chase Cancer Center
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT07167446 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study sites
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization · University of Pennsylvania / Abramson Cancer Center
- Registry record
- NCT04657068 · updated
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Thomas Jefferson University
- Study site
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Registry record
- NCT07417488 · updated
TCR1188-ABC Cells in KRAS-mutated Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- University of Pennsylvania
- Study site
- University of Pennsylvania
- Registry record
- NCT07594067 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- University of Pennsylvania, Perelman School of Medicine
- Registry record
- NCT05919264 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- Abramson Cancer Center of the University of Pennsylvania
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #98
- Registry record
- NCT05176483 · updated
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07277270 · updated
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Hospital of the University of Pennsylvania
- Registry record
- NCT06445062 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EvolveImmune United, Inc
- Study site
- Thomas Jefferson University, Sidney Kimmel Cancer Center
- Registry record
- NCT07217171 · updated
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Phase 1
- Ages 12 to 85
- All sexes
- Sponsor
- Inhibrx Biosciences, Inc
- Study sites
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research · University of Pennsylvania Abramson Cancer Center
- Registry record
- NCT03715933 · updated
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Fate Therapeutics
- Study site
- Thomas Jefferson University, Sidney Kimmel Cancer Center
- Registry record
- NCT07216105 · updated
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Phase 1/2
- From 12 months, up to 30 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Children's Hospital of Philadelphia
- Registry record
- NCT04851119 · updated
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Amgen
- Study site
- Thomas Jefferson University
- Registry record
- NCT07094113 · updated
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Jefferson University Hospitals
- Registry record
- NCT06179160 · updated
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Registry record
- NCT03947385 · updated
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Recursion Pharmaceuticals Inc.
- Study site
- University of Pennsylvania
- Registry record
- NCT05552755 · updated
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- 858 Therapeutics, Inc.
- Study site
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
- Registry record
- NCT06395519 · updated
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tasca Therapeutics
- Study site
- University of Pennsylvania
- Registry record
- NCT07030257 · updated
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Clasp Therapeutics, Inc.
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University, Sidney Kimmel Cancer Center
- Registry record
- NCT06778863 · updated
Adaptive Radiation Boost for Rectal Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Fox Chase Cancer Center
- Study site
- Fox Chase Cancer Center
- Registry record
- NCT07221058 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Ask about studies near Philadelphia
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
42 studies recruiting across 4 cities.
Pittsburgh
18 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections